Lexaria Bioscience Corp (LEXX)

$0.63 0.00 (-0.28%)
Market Cap 16.21M
Revenue (ttm) 710,000.00
Net Income (ttm) -11.90M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,676.06%
Debt to Equity Ratio 0.00
Volume 255,600
Avg Vol 728,036
Day's Range N/A - N/A
Shares Out 24.89M
Stochastic %K 29%
Beta 0.56
Analysts Strong Sell
Price Target $4.50

Company Profile

Lexaria Bioscience Corp. operates as a biotechnology company. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. Its DehydraTECH is...

Industry: Biotechnology
Sector: Healthcare
Phone: 250 765 6424
Address:
740 McCurdy Road, Suite 100, Kelowna, Canada
Shubeedoo
Shubeedoo Feb. 25 at 12:08 AM
$LEXX Some interesting trades after hours at .6631 and then .68. A few thousand shares and a few other smaller trades, an hour and a half after the close. Hhhhhhmmmmmmmmm
0 · Reply
Boston7452
Boston7452 Feb. 24 at 11:48 PM
$LEXX This little gem from CEO letter isnt really talked about!
0 · Reply
Turbofueled
Turbofueled Feb. 24 at 10:09 PM
$LEXX This is going to go wild!!! Hit it $LEXX
0 · Reply
TheRealStockRocket
TheRealStockRocket Feb. 24 at 8:28 PM
$LEXX Several here trying to load with negative rhetoric....just do it the right way...karma..This current prices will be long gone soon....long gone to the upside and everyone will say I wish I loaded more.
1 · Reply
hovian
hovian Feb. 24 at 8:14 PM
$LEXX looks like ask is fragile
0 · Reply
hovian
hovian Feb. 24 at 8:12 PM
$LEXX 300k shares eod? maybe 66 close? I ll love it
0 · Reply
Makingmillions192
Makingmillions192 Feb. 24 at 8:03 PM
$LEXX Got a nice fill this AM
0 · Reply
hovian
hovian Feb. 24 at 8:02 PM
$LEXX ups someone naked?
0 · Reply
hovian
hovian Feb. 24 at 8:02 PM
$LEXX maybe... 70 cents?
0 · Reply
hovian
hovian Feb. 24 at 7:43 PM
$LEXX 500k-1MM shares to dump... after that we can see 1.up tick... hope 60 cents is floor... and soon after dump will end reversal will put sp back to 70-80 cents
0 · Reply
Latest News on LEXX
Lexaria Announces Positive Final Results From Human Pilot Study #5

Feb 5, 2026, 9:15 AM EST - 19 days ago

Lexaria Announces Positive Final Results From Human Pilot Study #5

Lexaria Awarded Six Additional Patents

Jan 22, 2026, 9:20 AM EST - 4 weeks ago

Lexaria Awarded Six Additional Patents

Lexaria Releases Annual Letter from the CEO

Jan 12, 2026, 9:10 AM EST - 6 weeks ago

Lexaria Releases Annual Letter from the CEO

Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4

Dec 30, 2025, 9:20 AM EST - 2 months ago

Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4

Lexaria Says Oral GLP-1 Cuts Side Effects Nearly 50% Versus Novo Nordisk's Rybelsus

Dec 23, 2025, 12:06 PM EST - 2 months ago

Lexaria Says Oral GLP-1 Cuts Side Effects Nearly 50% Versus Novo Nordisk's Rybelsus

NVO

Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4

Dec 23, 2025, 9:29 AM EST - 2 months ago

Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4

Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 16, 2025, 4:00 PM EST - 2 months ago

Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 15, 2025, 8:00 AM EST - 2 months ago

Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

Nov 12, 2025, 9:10 AM EST - 3 months ago

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

Lexaria Bioscience Corp. Provides Strategic Update

Oct 9, 2025, 9:20 AM EDT - 4 months ago

Lexaria Bioscience Corp. Provides Strategic Update

Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Sep 29, 2025, 4:30 PM EDT - 5 months ago

Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Sep 26, 2025, 8:10 AM EDT - 5 months ago

Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Lexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain

Sep 19, 2025, 11:20 AM EDT - 5 months ago

Lexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain

Lexaria Attending the 27th Annual H.C. Wainwright Global Investment Conference

Aug 27, 2025, 9:20 AM EDT - 6 months ago

Lexaria Attending the 27th Annual H.C. Wainwright Global Investment Conference

Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone

Aug 14, 2025, 9:20 AM EDT - 6 months ago

Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone

GLP-1 "Arms Race" Broadens to Include Dozens of Companies

Aug 6, 2025, 9:20 AM EDT - 7 months ago

GLP-1 "Arms Race" Broadens to Include Dozens of Companies

Lexaria Provides Positive Interim Results on Partial 8-week Data From Phase 1b, GLP-1-H24-4 Study

Jul 28, 2025, 9:25 AM EDT - 7 months ago

Lexaria Provides Positive Interim Results on Partial 8-week Data From Phase 1b, GLP-1-H24-4 Study

Lexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 Study

Jul 28, 2025, 9:25 AM EDT - 7 months ago

Lexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 Study

Lexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-Industry

Jul 23, 2025, 9:25 AM EDT - 7 months ago

Lexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-Industry

Lexaria Reaches Patent Milestone - 50 Patents Now Granted Worldwide

Jun 23, 2025, 9:15 AM EDT - 8 months ago

Lexaria Reaches Patent Milestone - 50 Patents Now Granted Worldwide

Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule

Jun 11, 2025, 9:05 AM EDT - 9 months ago

Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule

Lexaria Attending BIO International Convention

Jun 5, 2025, 9:20 AM EDT - 9 months ago

Lexaria Attending BIO International Convention

Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company

May 12, 2025, 9:00 AM EDT - 10 months ago

Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company

Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock

Apr 28, 2025, 4:15 PM EDT - 10 months ago

Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock

Lexaria Announces $2 Million Registered Direct Offering of Common Stock

Apr 25, 2025, 8:00 AM EDT - 10 months ago

Lexaria Announces $2 Million Registered Direct Offering of Common Stock

Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience's Technology

Apr 23, 2025, 9:10 AM EDT - 10 months ago

Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience's Technology

Lexaria Updates its Ongoing Human Study GLP-1-H24-4

Apr 3, 2025, 9:10 AM EDT - 11 months ago

Lexaria Updates its Ongoing Human Study GLP-1-H24-4

Lexaria's Human GLP-1 Study #5 Begins Dosing

Apr 2, 2025, 9:05 AM EDT - 11 months ago

Lexaria's Human GLP-1 Study #5 Begins Dosing

Lexarias' DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable Zepbound

Mar 18, 2025, 9:15 AM EDT - 1 year ago

Lexarias' DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable Zepbound

Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable Zepbound(R)

Mar 18, 2025, 9:15 AM EDT - 1 year ago

Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable Zepbound(R)

The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience

Feb 27, 2025, 8:00 AM EST - 1 year ago

The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience

Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm

Feb 24, 2025, 8:00 AM EST - 1 year ago

Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm

Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide

Feb 20, 2025, 8:00 AM EST - 1 year ago

Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide

Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy

Feb 11, 2025, 8:00 AM EST - 1 year ago

Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy

Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway

Feb 6, 2025, 9:40 AM EST - 1 year ago

Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway

Lexaria's Human GLP-1 Study #5 Receives Independent Review Board Approval

Jan 15, 2025, 9:20 AM EST - 1 year ago

Lexaria's Human GLP-1 Study #5 Receives Independent Review Board Approval

Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R)

Jan 14, 2025, 9:10 AM EST - 1 year ago

Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R)

Lexaria's Registered GLP-1 Study #4 Begins Dosing

Dec 19, 2024, 9:05 AM EST - 1 year ago

Lexaria's Registered GLP-1 Study #4 Begins Dosing

Lexaria Forms New Scientific Advisory Board

Dec 18, 2024, 9:25 AM EST - 1 year ago

Lexaria Forms New Scientific Advisory Board

Esteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria Bioscience

Dec 17, 2024, 9:10 AM EST - 1 year ago

Esteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria Bioscience

Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5

Dec 9, 2024, 9:10 AM EST - 1 year ago

Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5

Revolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs

Nov 26, 2024, 9:20 AM EST - 1 year ago

Revolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs

Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled

Nov 25, 2024, 9:00 AM EST - 1 year ago

Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled

ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study

Nov 20, 2024, 9:05 AM EST - 1 year ago

ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study

Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study

Nov 14, 2024, 9:10 AM EST - 1 year ago

Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study

Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss

Nov 13, 2024, 9:20 AM EST - 1 year ago

Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss

Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments

Nov 7, 2024, 9:15 AM EST - 1 year ago

Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments

Positive Partial 12-Week Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study

Oct 24, 2024, 9:10 AM EDT - 1 year ago

Positive Partial 12-Week Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study

Positive Partial 12-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study

Oct 22, 2024, 9:20 AM EDT - 1 year ago

Positive Partial 12-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study

Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Oct 16, 2024, 4:00 PM EDT - 1 year ago

Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Shubeedoo
Shubeedoo Feb. 25 at 12:08 AM
$LEXX Some interesting trades after hours at .6631 and then .68. A few thousand shares and a few other smaller trades, an hour and a half after the close. Hhhhhhmmmmmmmmm
0 · Reply
Boston7452
Boston7452 Feb. 24 at 11:48 PM
$LEXX This little gem from CEO letter isnt really talked about!
0 · Reply
Turbofueled
Turbofueled Feb. 24 at 10:09 PM
$LEXX This is going to go wild!!! Hit it $LEXX
0 · Reply
TheRealStockRocket
TheRealStockRocket Feb. 24 at 8:28 PM
$LEXX Several here trying to load with negative rhetoric....just do it the right way...karma..This current prices will be long gone soon....long gone to the upside and everyone will say I wish I loaded more.
1 · Reply
hovian
hovian Feb. 24 at 8:14 PM
$LEXX looks like ask is fragile
0 · Reply
hovian
hovian Feb. 24 at 8:12 PM
$LEXX 300k shares eod? maybe 66 close? I ll love it
0 · Reply
Makingmillions192
Makingmillions192 Feb. 24 at 8:03 PM
$LEXX Got a nice fill this AM
0 · Reply
hovian
hovian Feb. 24 at 8:02 PM
$LEXX ups someone naked?
0 · Reply
hovian
hovian Feb. 24 at 8:02 PM
$LEXX maybe... 70 cents?
0 · Reply
hovian
hovian Feb. 24 at 7:43 PM
$LEXX 500k-1MM shares to dump... after that we can see 1.up tick... hope 60 cents is floor... and soon after dump will end reversal will put sp back to 70-80 cents
0 · Reply
Makingmillions192
Makingmillions192 Feb. 24 at 6:37 PM
$LEXX Lexaria to negative 0!!!!
1 · Reply
LOSINGMILLIONS
LOSINGMILLIONS Feb. 24 at 6:31 PM
$LEXX I’m just surprised when I sell off some of my shares anybody is willing to buy them.
0 · Reply
7_Angus_1
7_Angus_1 Feb. 24 at 5:57 PM
$LEXX I'll take 1% of that $35B from $NVO. "Investors' focus will likely now turn to management's M&A strategy, in our view, with our forecasts suggesting potential for up to $35 billion to be spent this year." https://www.reuters.com/business/healthcare-pharmaceuticals/view-novos-cagrisema-setback-may-shift-investor-focus-ma-strategy-analysts-say-2026-02-23/
0 · Reply
Makingmillions192
Makingmillions192 Feb. 24 at 5:41 PM
$LEXX Lexaria to 0!!!
0 · Reply
Boston7452
Boston7452 Feb. 24 at 5:37 PM
$LEXX The big pharma lex ”caught the attention of” may not be their MTA partner. Important distinction.
2 · Reply
Makingmillions192
Makingmillions192 Feb. 24 at 5:32 PM
$LEXX It seems like the more negative I get the better the stock does
0 · Reply
harlem111
harlem111 Feb. 24 at 5:00 PM
$LEXX I see a deal any day now as SOS of years of R/S with another raise or two or three. Keeping my shares (not worth much today) and take a tax write off over time - miracle at this point is to get my money back! not holding my breath for that. GLTA
0 · Reply
Makingmillions192
Makingmillions192 Feb. 24 at 4:50 PM
$LEXX Continued dump fest on the bid @hovian was right
0 · Reply
Makingmillions192
Makingmillions192 Feb. 24 at 4:33 PM
$LEXX Because we hired a CEO that ran his last company into the ground diluting it until it was gone. BUT Bunka told everyone this was the guy since he was on the bandwagon of the company that got acquired 13 years ago. And we paid him 1.1M so far to drop the stock 81%. Not surprising that right after the CEO got appointed in 2024 Sabby aggressively started shorting this and we did a private placement deal directly with him to cover his position. He then proceeded to CRUSH any momentum with large raises and warrants attached to stop ANY price advances. Highly questionable why Bunka put him in place. Is that to pessimistic? 😂
0 · Reply
Shubeedoo
Shubeedoo Feb. 24 at 4:32 PM
$LEXX 1b results have been available to the alleged "major pharma" MTA partner. If the news was good, we would not be trailing off again and again, with sellers waiting at every penny. News does leak, and people to buy on hints and speculation. Something is not right here and/or there will be a much, much longer wait than anyone expected. Guess we will have to wait until we get much closer to April 30, but expectations have to be tapered in a pretty dramatic way.
1 · Reply
Taco_stocks
Taco_stocks Feb. 24 at 4:30 PM
$LEXX Looks like we are heading into the .50s
0 · Reply
harlem111
harlem111 Feb. 24 at 4:29 PM
$LEXX The pps should be going up - How is it that the pps keeps dying as it is virtually impossible to keep a deal in the making 100% quiet -- usually with some share buyers in the know? Feels like more of the SOS from Bunka over the y ears. Holding but concerned
1 · Reply